Repligen (NasdaqGS:RGEN) FY Conference December 03, 2025 01:20 PM ET Company ParticipantsStephen Shah - Head of Investor RelationsJason Garland - CFOConference Call ParticipantsDaniel Markowitz - AnalystDaniel MarkowitzAre we live? Great. Awesome. Thank you, everyone, for joining. For those of you who don't know me, I'm Daniel Markowitz. I cover the life science, tools, and diagnostics and med tech space here at Evercore ISI. Today we're joined by Repligen. We have with us CFO Jason Garland and, from Invest ...

Group 1 - Prominent private equity firm Tongyuan Investment recently conducted research on two listed companies [1] - Changchun High-tech has made significant progress in using AI large models to design highly alkaline single-domain antibodies, successfully completing the development of a protein product designed by the large model that has entered 5000-liter scale production [1] Group 2 - Core International has seen structural changes in the recruitment market this year, with real demand being high and a greater emphasis on professional consulting [2] - The company's performance growth is driven by internal factors, including technological investment, multi-product layout, and deepening vertical fields [2] - The demand for part-time experts is expanding, covering short-term projects and ERP positions, with the He Wa platform's offer growth outpacing revenue due to conversion cycle differences [2] - The flexible employment business relies on a strategy of large clients and expanding long-tail clients, with continuous optimization of the client structure [2] - AI Agent is being applied in various scenarios such as recruitment, payroll calculation, and automation to enhance productivity, currently undergoing internal testing [2] - The launch of He Wa I2.0 has led to significant data growth, which is expected to drive platformization and ecosystem development in the recruitment industry [2]

Genscript Biotech (01548) H2 2024 Earnings Call March 12, 2025 08:40 AM ET Company Participants Shiniu Wei - Chief Financial OfficerWeihui Shao - CEO & COORay Chen - President of GenScript Life Science Group Conference Call Participants Daisy Cheng - AnalystLinhai Percy Zhao - Equity Research AnalystNone - Analyst Operator Good day and thank you for standing by. Welcome to Gentscript BioTech twenty twenty four Annual Results Conference Call. At this time, all participants are in a listen only mode. After th ...